Genomic and epigenomic data suggest it may be possible to target an FGFR fusion found in open chromatin in a subset of adenosquamous carcinoma of the pancreas tumors.
The group believes that being able to track ctDNA changes down to the lowest possible levels may be necessary for liquid biopsy to monitor treatment in early-stage cancers.
The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.
An affiliation with City of Hope, the advent of Illumina NovaSeq, and the availability of HPC flash storage have changed the nature of high-performance computing at TGen.
Investigators are studying samples from a group of 100 patients to try to lock down patterns in circulating tumor DNA that can be used to validate monitoring methods for the clinic.
The project aims to use circulating tumor DNA to monitor drug response and resistance in metastatic melanoma patients in order to guide treatment decisions.
